Navigation Links
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
Date:9/9/2008

ternal medicine with a subspecialty in endocrinology and metabolism.

"We are very pleased to have Ken join Intarcia Therapeutics to lead our hepatitis C and diabetes clinical development efforts," said Alice Leung. "Ken's drug development experience and expertise in the areas of diabetes and metabolic diseases are tremendous assets as we prepare to initiate clinical development of ITCA 650 for the treatment of type 2 diabetes. We look to his significant clinical and development expertise as we bring Omega DUROS therapy into later stages of development as well as expand the Company's pipeline in the metabolic diseases area."

Intarcia is currently conducting a phase 1 study of Omega DUROS therapy in combination with ribavirin for the treatment of patients with HCV genotype-1 who have failed prior standard of care treatment. In addition, Intarcia is preparing to initiate a phase 1 clinical trial of ITCA 650 in the first quarter of 2009 for the treatment of type 2 diabetes. Both of these programs use Intarcia's proprietary subcutaneous DUROS drug delivery technology that provides continuous and consistent administration of drug therapy.

Dr. Luskey said, "Intarcia represents a very unique opportunity. I believe the proven advantages of the DUROS delivery technology hold great potential in developing more effective treatments for many chronic diseases, including hepatitis C and type 2 diabetes. I am very excited to join Intarcia at this stage of the Company's development and look forward to directing clinical programs to fulfill the potential of DUROS delivery in these two disease areas."

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent ma
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Reverse Stock Split
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
4. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
7. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
8. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
9. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  AsureQuality and Ubiquitome ... testing for applications in food and primary production ... powered real-time PCR device, the Freedom4. ... through to the supermarket shelf for producers, processors ... involvement in animal disease control and pest management ...
(Date:7/29/2015)... DUBLIN , July 29, 2015 ... ) has announced the addition of the ... to their offering. The Global Biosimilars ... study of the rapidly growing biosimilars market. With ... industry striving to minimize costs, biosimilars are being ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  Pfenex ... quarter 2015 financial results will be released on Thursday, ... 8:30 am Eastern Time, Pfenex management will host a ... a business update.  A press release outlining the financial ... to the call. Please call 1-866-376-8058 (US) ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
... , LUMBY, BC, Oct. 2 /PRNewswire-FirstCall/ - avVaa World ... biotechnology company, manufacturer and distributor of nationally branded therapeutic, ... that will feature their Neuroskin(R) Psoriasis Relief DRTV commercial ... Health Care Products Inc. is launching a two week ...
... ... pharmaceuticalstability.com , ... Mountain, NC (PRWEB) October 2, 2009 -- Parameter Generation and Control, Inc (PGC) and ... new catalog and web site called "Pharmaceutical Stability Solutions". This brochure and website ...
... PHILADELPHIA and LONDON, Oct. 1 Thomson Reuters announced ... and challenges facing foreign companies interested in entering the ... titled "The Japanese generic drug market: opportunities and strategies ... expirations prior to 2012, a rapidly aging population and ...
Cached Biology Technology:avVaa World Health Care Products Inc. Announces DRTV Test Television Stations 2avVaa World Health Care Products Inc. Announces DRTV Test Television Stations 3Parameter Generation and Control Launches New Catalog "Pharmaceutical Stability Solutions" 2Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market 2Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market 3
(Date:7/23/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) has ... of the Biometrics Industry 2015 " report ... biometrics market is likely to witness significant growth ... the uptake of multiple technologies available. The year ... growth of biometrics in existing applications as well ...
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... seismic images yet of the Chicxulub crater, a mostly submerged ... a theory explaining the extinction of 70 percent of life ... was formed when an asteroid struck on the coast of ... major role in the KT Extinction Event that caused the ...
... lustrous pigments to make their buildings dazzle in the daylight, ... tiny shards of paint from the Mayan city of Copan, ... evidence of mica that would have made the buildings glitter ... mica was applied over the red paint of stucco masks ...
... Award-Winning Fingerprint Recognition Solution for HIPAA ... ... Operational Efficiencies, ATLANTA, Jan. 22 M2SYS Technology, ... has enhanced its OnRecord(TM) healthcare solution for emergency,departments and ...
Cached Biology News:Seismic images show dinosaur-killing meteor made bigger splash 2QUT researcher discovers Maya mask splendor 2LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 2
... can be used for the identification of potential ... renal and other diseases. Due to the fact ... amounts, it provides an attractive alternative to blood ... The ProteoSpin Urine Protein Concentration Micro Kit ...
... Vibratome Company has joined forces with the ... Vibratome 411301 Tissue Chopper. This tissue sectioning ... of tissue for metabolic experiments and to ... specimens available at biopsy or from small ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... joined forces with the Mickle Laboratory Engineering ... Chopper. This tissue sectioning system has been ... metabolic experiments and to be especially applicable ... biopsy or from small organs. Its special ...
Biology Products: